# Phase 1 → Phase 2 Decision Matrix

## Phase 1 Success Criteria

Run the full 3-fold CV experiment (`SSL_KD.py`) and evaluate results against these criteria:

### 🎯 **Minimum Viable Results (Workshop Paper)**

| Metric | Threshold | Rationale |
|--------|-----------|-----------|
| **SSL Gain** | DSC ≥ +0.03 | Meaningful improvement over random init |
| **KD Gain** | DSC ≥ +0.01 | KD provides additional benefit |
| **Statistical Significance** | p < 0.05 | Paired t-test across 3 folds |
| **Upper Bound Gap** | ≤ 0.15 DSC | SSL+KD gets reasonably close to supervised |
| **Reproducibility** | CV std ≤ 0.05 | Results are stable across folds |

### 📊 **Example Results Analysis**

```
Results from 3-fold CV:
Method                         DSC (mean ± std)     
----------------------------------------------------------------------
Supervised UB (all labels)     0.847 ± 0.023       
Baseline (random, 1 label)     0.651 ± 0.041       
SSL only (SparK, 1 label)      0.689 ± 0.038       ✅ +0.038 gain
SSL + KD (SparK, 1 label)      0.712 ± 0.035       ✅ +0.023 gain

SSL gain over baseline   :  +0.038 DSC  ✅ > 0.03 threshold
KD  gain over SSL-only   :  +0.023 DSC  ✅ > 0.01 threshold  
SSL+KD closes 31.1% of gap to supervised UB  ✅ Reasonable gap closure
```

**Decision: ✅ PROCEED TO PHASE 2** — Results exceed all thresholds

---

## Decision Tree

### 🟢 **Strong Results → Full Conference Paper (Phase 2)**

**If you achieve:**
- SSL gain ≥ +0.05 DSC
- KD gain ≥ +0.02 DSC  
- Gap closure ≥ 40%
- All results statistically significant

**Then invest 4-6 weeks in Phase 2:**
- Multi-organ validation (liver, pancreas)
- Additional SSL baselines (SimCLR, random crops)
- KD hyperparameter ablation
- Computational efficiency analysis
- Target: MICCAI main conference

### 🟡 **Moderate Results → Workshop Paper (Phase 1 Only)**

**If you achieve:**
- SSL gain: +0.03 to +0.05 DSC
- KD gain: +0.01 to +0.02 DSC
- Gap closure: 20-40%
- Some statistical significance

**Then finalize Phase 1 paper:**
- Write 4-page workshop paper
- Submit to MICCAI LABELS, IEEE ISBI
- Timeline: 1-2 weeks to submission
- Expected outcome: Workshop acceptance

### 🔴 **Weak Results → Pivot or Debug**

**If you achieve:**
- SSL gain < +0.03 DSC
- KD gain < +0.01 DSC  
- No statistical significance
- High variance across folds

**Then either:**
1. **Debug approach** — Check KD loss scaling, hyperparameters
2. **Pivot to different story** — Focus on SSL only, different dataset
3. **Abandon for now** — Results not publication-worthy

---

## Phase 2 Extension Plan

### 🚀 **Additional Experiments (4-6 weeks)**

**Multi-Organ Validation:**
```python
# Test generalization across organs
organs = ["heart", "liver", "pancreas"]
for organ in organs:
    run_ssl_kd_experiment(organ, n_folds=3)
```

**SSL Baseline Comparison:**
```python
ssl_methods = [
    "random_init",      # Current baseline
    "random_crops",     # Simple augmentation baseline  
    "simclr",          # Contrastive learning
    "spark",           # Current method
]
```

**KD Hyperparameter Ablation:**
```python
kd_configs = [
    {"alpha": 0.5, "temperature": 1.0},
    {"alpha": 1.0, "temperature": 2.0},  # Current
    {"alpha": 2.0, "temperature": 4.0},
    {"alpha": 1.0, "temperature": 8.0},
]
```

**Computational Analysis:**
- Training time comparison
- Memory usage analysis  
- Inference speed benchmarks
- Model size comparison

### 📝 **Phase 2 Paper Structure (6-8 pages)**

1. **Introduction** (1 page) — Few-shot medical segmentation challenge
2. **Related Work** (1 page) — SSL methods, KD in medical imaging
3. **Method** (1.5 pages) — SparK+KD pipeline, implementation details
4. **Experiments** (3 pages) — Multi-organ results, ablations, comparisons
5. **Discussion** (1 page) — Analysis, limitations, clinical implications
6. **Conclusion** (0.5 pages) — Contributions, future work

---

## Timeline & Resource Planning

### Phase 1 Completion
- **Week 1:** Run validation script, debug issues
- **Week 2:** Run full 3-fold CV experiment  
- **Week 3:** Analyze results, make Phase 2 decision

### Phase 2 (If Proceeding)
- **Weeks 4-5:** Multi-organ experiments
- **Weeks 6-7:** Additional baselines and ablations
- **Weeks 8-9:** Paper writing and submission prep

### Submission Deadlines
- **MICCAI LABELS Workshop:** March 2024 (Phase 1 sufficient)
- **IEEE ISBI:** November 2024 (Phase 1 sufficient)  
- **MICCAI Main Conference:** March 2024 (Phase 2 required)
- **Medical Image Analysis:** Rolling (Phase 2 preferred)

---

## Risk Assessment

### 🔴 **High Risk Factors**
- Small dataset (20 volumes) → High variance
- Single institution data → Limited generalizability  
- No comparison to recent medical SSL methods
- KD may not provide significant benefit

### 🟡 **Medium Risk Factors**  
- 3-fold CV may be underpowered statistically
- Heart segmentation is relatively "easy" task
- Limited novelty (existing methods combined)

### 🟢 **Low Risk Factors**
- Solid experimental design
- Reproducible implementation
- Clear clinical motivation
- Established evaluation metrics

---

## Success Probability Estimates

| Outcome | Phase 1 | Phase 2 |
|---------|---------|---------|
| **Workshop Acceptance** | 70% | 85% |
| **Conference Poster** | 30% | 60% |
| **Conference Oral** | 5% | 20% |
| **Journal Acceptance** | 10% | 40% |

**Recommendation:** Phase 1 is low-risk with decent publication probability. Phase 2 significantly improves chances but requires substantial additional work.

---

## Next Steps

1. **Run Phase 1 validation:** `python phase1_validation.py`
2. **Run full experiment:** Execute `SSL_KD.py` notebook  
3. **Analyze results:** Compare against thresholds above
4. **Make decision:** Use this matrix to decide on Phase 2
5. **Plan timeline:** Align with submission deadlines

**Key Decision Point:** If Phase 1 results exceed moderate thresholds and you have 4-6 weeks available, Phase 2 is recommended for stronger publication venue.